Evaluation of candidate vaccine approaches for MERS-CoV.

Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou T, Yassine HM, Kanekiyo M, Yang ZY, Chen X, Becker MM, Freeman M, Vogel L, Johnson JC, Olinger G, Todd JP, Bagci U, Solomon J, Mollura DJ, Hensley L, Jahrling P, Denison MR, Rao SS, Subbarao K, Kwong PD, Mascola JR, Kong WP, Graham BS. · 2015

Read Evaluation of candidate vaccine approaches for MERS-CoV. by Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou T, Yassine HM, Kanekiyo M, Yang ZY, Chen X, Becker MM, Freeman M, Vogel L, Johnson JC, Olinger G, Todd JP, Bagci U, Solomon J, Mollura DJ, Hensley L, Jahrling P, Denison MR, Rao SS, Subbarao K, Kwong PD, Mascola JR, Kong WP, Graham BS. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4525294.txt.

Introduction

Lingshu Wang leads a twelve-author team testing vaccine designs against MERS in Nature Communications in 2015. The MERS coronavirus causes severe lung disease, and no vaccine existed. Earlier efforts focused on one piece of the virus's spike protein, the part that grabs host cells. The team reasoned that a narrow target might miss the strongest antibody responses.

Vaccines built on the full spike DNA, or on its S1 subunit as a protein, raised strong neutralizing antibodies in mice and monkeys against several virus strains. The antibodies hit the grabbing region and other spike parts too, and blocked the virus by more than one route. Vaccinated rhesus macaques were protected from pneumonia on scans after challenge, supporting full-spike designs.

Catalog record

CREATORWang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou T, Yassine HM, Kanekiyo M, Yang ZY, Chen X, Becker MM, Freeman M, Vogel L, Johnson JC, Olinger G, Todd JP, Bagci U, Solomon J, Mollura DJ, Hensley L, Jahrling P, Denison MR, Rao SS, Subbarao K, Kwong PD, Mascola JR, Kong WP, Graham BS.
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE65 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4525294

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Evaluation of candidate vaccine approaches for MERS-CoV By Lingshu Wang, Wei Shi, M. Gordon Joyce, Kayvon Modjarrad, Yi Zhang, Kwanyee Leung, Christopher R. Lees, Tongqing Zhou, Hadi M. Yassine, Masaru Kanekiyo, Zhi-yong Yang, Xuejun Chen Published in: Nature Communications DOI: 10.1038/ncomms8712 ABSTRACT The emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) as a cause of severe respiratory disease highlights the need for effective approaches to CoV vaccine development. Efforts focused solely on the receptor-binding domain (RBD) of the viral Spike (S) glycoprotein may not optimize neutralizing antibody (NAb) responses. Here we show that immunogens based on full-length S DNA and S1 subunit protein elicit robust serum-neutralizing activity against several MERS-CoV strains in mice and non-human primates. Serological analysis and isolation of murine monoclonal antibodies revealed that immunization elicits NAbs to RBD and, non-RBD portions of S1 and S2 subunit. Multiple neutralization mechanisms were demonstrated by solving the atomic structure of a NAb-RBD complex, through sequencing of neutralization escape viruses and by constructing MERS-CoV S variants for serological assays. Immunization of rhesus macaques confers protection against MERS-CoV-induced radiographic pneumonia, as assessed using computerized tomography, supporting this strategy as a promising approach for MERS-CoV vaccine development. Supplementary information The online version of this article (doi:10.1038/ncomms8712) contains supplementary material, which is available to authorized users. INTRODUCTION Middle East respiratory syndrome coronavirus (MERS-CoV) has emerged as a highly fatal cause of severe acute respiratory infection. Since April 2012, 1,348 cases and 479 deaths in over twenty-five countries have been attributed to this novel beta-coronavirus1,2. As human-to-human transmission of the virus is not sustained, a large zoonotic reservoir may serve as a principal source for transmission events3,4,5,6. The high case fatality rate, vaguely defined epidemiology, and absence of prophylactic or therapeutic measures against this novel virus have created an urgent need for an effective vaccine should the outbreak expand to pandemic proportions. Past efforts to develop coronavirus vaccines have used whole-inactivated virus, live-attenuated virus, recombinant protein subunit or genetic approaches7. The primary target for neutralizing antibodies is the Spike (S) glycoprotein, cleaved into two subunits: S1, which is distal to the virus membrane and S2, which contains both a transmembrane domain and two heptad-repeat sequences typical of class I fusion glycoproteins8,9. The S1 subunit has been the focus of most immunization strategies against MERS-CoV10,11,12, as it contains the receptor-binding domain (RBD) that mediates virus attachment to its host receptor, dipeptidyl peptidase-4 (DPP4)13. Expressing the RBD on multiple vaccine platforms can elicit neutralizing antibodies of high potency14,15,16,17,18 that prevent viral attachment across many strains but will not elicit antibodies that contribute to neutralization through fusion inhibition. We developed an alternative vaccine regimen, based on full-length S DNA and a truncated S1 subunit glycoprotein, to elicit a broad repertoire of antibodies with diverse mechanisms of viral neutralization, and found that immunization with these constructs protected non-human primates (NHPs) from severe lung disease after intratracheal challenge with MERS-CoV. RESULTS Spike glycoprotein immunogen construction and characterization We originally designed five vaccine constructs on the basis of sequences from the MERS-CoV Spike glycoprotein (Fig. 1a). The England1 strain (GenBank ID: AFY13307) was chosen on the basis of the availability of its sequence and its proximity to a consensus among published sequences, particularly within the RBD. We constructed three plasmid vaccines that encoded (1) full-length, membrane-anchored Spike; (2) transmembrane-deleted (ΔTM) Spike containing the entire ectodomain; and (3) S1 subunit only. All three plasmids were delivered intramuscularly by needle and syringe, followed by electroporation. The two protein subunit vaccines included S-ΔTM and S1 and were delivered intramuscularly by needle and syringe with Ribi adjuvant. These five candidate vaccines were systematically evaluated in mice according to eight immunization regimens (Fig. 1a). To test the immunogenicity of our vaccine candidates against multiple MERS-CoV strains—without the requirement of a biosafety level 3 facility—we developed a pseudotyped reporter virus neutralization assay, as we did previously for SARS-CoV19,20,21,22. We confirmed that the assay measured viral entry via the MERS-CoV receptor, DPP4, by demonstrating that HEK 293 cells required DPP4 expression on their surface for efficient infection and that soluble DPP4 or anti-DPP4 antibody prevented infection (Supplementary Fig. 1a–d).Figure 1MERS-CoV Spike glycoprotein vaccine design and immunogenicity in mice.Candidate vaccine immunogens were designed on the basis of the Spike glycoprotein sequence of the England1 MERS coronavirus and elicited high neutralization titres. (a) Schematic representation of MERS-CoV Spike protein cDNAs and recombinant proteins. Five vaccine constructs were made: three DNA and two protein subunits. DNA constructs consisted of full-length Spike or truncated versions that either had the transmembrane domain or the entire S2 subunit deleted. The protein constructs contain either a truncated Spike molecule with the transmembrane domain deleted (S-ΔTM) or the S1 subunit. RBD, receptor-binding domain; SP, signal peptide; TM, transmembrane domain; FTH, foldon (trimerization domain), thrombin (cleavage site) followed by histidine tag; 3CHis, Human rhinovirus 3C protease cleavage site, followed by 6 × histidine tag. (b) Immunogenicity of eight vaccine regimens. Five mice per group were immunized with plasmid DNA only at weeks 0, 3 and 6 (groups 1–3); plasmid DNA at weeks 0 and 3 and protein plus Ribi adjuvant at week 6 (groups 4–6); or protein plus Ribi adjuvant at weeks 0 and 4 (groups 7 and 8). Two weeks after each immunization, sera were collected and neutralizing antibody titres were measured against pseudotyped MERS-CoV England1 virus. Open, grey and black bars, respectively, represent the IC90 neutralization titres (GMT from five mice per group with 95% confidence interval) from the post-prime, first post-boost and second post-boost sera. Each sample was tested in triplicate; all assays were repeated once. A nonparametric two-tailed t-test (Mann–Whitney) was used for statistical analysis, and the relevant P values are indicated. (c) MERS-CoV vaccines induced cross-neutralization to eight MERS-CoV strains. The sera from the mice immunized with MERS-CoV S DNA three times, primed with S DNA and boosted with S1 protein plus Ribi adjuvant, or primed and boosted with S1 protein plus Ribi adjuvant were assayed for neutralization to the eight strains of MERS-CoV and SARS-CoV pseudotyped viruses as indicated. IC90 titre is shown. Data are presented as the mean of triplicates with s.e.’s. Full-length S DNA and S1 protein elicit high titers of NAb in mice Mice primed either once with S1 protein or twice with S DNA and then boosted once with S1 protein generated the highest neutralizing antibody (NAb) titres among all groups (Fig. 1b). The full-length S DNA regimen induced a significantly higher antibody response than the truncated S-ΔTM or S1 DNA regimens. Antibody titres tended to be either low or undetectable after the first dose of DNA but were boosted 10-fold after immunization with S1 protein. Two doses of S1 protein achieved an IC90 neutralization titer (90% inhibitory concentration) near that of the DNA/protein regimen. Three of the eight vaccine regimens— S DNA, S DNA-S1 protein and S1 protein alone—were carried forward for detailed evaluation. S-ΔTM gave low production yields from transfected HEK 293 cells and was not evaluated further. Immune sera (5 weeks after final boost) from these three regimens were tested against a panel of eight pseudoviruses and found to generate equally robust NAb titres against all strains (Fig. 1c). The sequence homology across strains (Supplementary Fig. 2) likely accounted for the breadth of neutralization.

Read the complete text